Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Revvity Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.5, while Revvity Inc trades at $106.58 (market cap $11.87B). The key difference: Revvity Inc pays a 0.26% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Revvity Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | RVTY | |
|---|---|---|
52-Week High | $97.99 | $117.75 |
52-Week Low | $93.11 | $82.26 |
Market Cap | — | $11.87B |
Sector | — | Technology |
Enterprise Value | — | $14.36B |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF (iShares 7-10 Year Treasury Bond ETF) trades at $93.54, down 0.32% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 58.33, while bond market uncertainty persists amid Federal Reserve policy speculation. Recent dividend payments of $0.31-$0.32 reflect steady income distribution to shareholders.
The outlook remains cautious as bond ETFs face pressure from potential rate hikes and inflation concerns. Investment opportunity lies in Treasury exposure for portfolio diversification, though risks include interest rate sensitivity and macroeconomic volatility affecting bond valuations.
RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.
The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
